Quince Therapeutics, Inc.

QNCX Nasdaq CIK: 0001662774

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation CA
Business Address 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080
Phone 415-910-5717
Fiscal Year End 1231
EIN 901024039

Financial Overview

FY2024

$167.90M
Total Assets
$100.59M
Stockholders' Equity
$-0.84
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 12, 2026 View on SEC
8-K Current report of material events February 2, 2026 View on SEC
8-K Current report of material events January 29, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 21, 2026 View on SEC
4 Insider stock transaction report January 21, 2026 View on SEC
4 Insider stock transaction report January 21, 2026 View on SEC
4 Insider stock transaction report January 21, 2026 View on SEC

Material Events

8-K Strategy Change January 29, 2026
High Impact
  • Quince Therapeutics' lead drug candidate, eDSP, failed its Phase 3 clinical trial (NEAT) for Ataxia-Telangiectasia (A-T), not achieving primary or key secondary goals.
  • The company has immediately halted all clinical development of eDSP.
View Analysis

Insider Trading

SELL 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.